Abstract:
A fuel gas delivery system is provided. The fuel gas delivery system includes a feed line configured to provide a natural gas stream and a cryocooler fluidly coupled to the feed line. The cryocooler is configured to condense the natural gas to provide a liquefied natural gas (LNG) stream and to freeze impurities contained in the natural gas stream. The frozen impurities are separated from said LNG stream. A first heat exchanger is fluidly coupled to the cryocooler and the first heat exchanger is configured to vaporize at least a portion of the LNG stream to provide compressed natural gas. A delivery line is configured to supply the compressed natural gas to an end user and a removal line is configured to remove the impurities from the fuel gas delivery system.
Abstract:
A method and an apparatus for producing hyperpolarized samples for use in magnetic resonance imaging (MRI) are provided. The apparatus comprises an ultra- compact cryogen-free cryostat structure for use in polarizing a sample of selected material, wherein the- cryostat structure comprises a central bore (6) being adapted to be evacuated to create a vacuum region, and a cooling device (210, 260) inserted in the central bore or optionally close to the central bore for maintaining a selected temperature of the sample.
Abstract:
A superconducting magnet assembly and method of cooling a superconducting magnet assembly includes thermally connecting a pulsating heat pipe to the superconducting magnet assembly and adding a liquid cryogen to the pulsating heat pipe. The superconducting magnet assembly also includes a coil former, at least one superconducting solenoid magnet comprising at least one superconducting winding wrapped about the coil former and configured to generate a magnetic field, and at least one pulsating heat pipe thermally connected to the at least one superconducting solenoid magnet. The present invention has been described in terms of specific embodiment(s), and it is recognized that equivalents, alternatives, and modifications, aside from those expressly stated, are possible and within the scope of the appending claims.
Abstract:
A fluid path system includes a vial containing a pharmaceutical product therein. A dissolution fluid path is also included in the fluid path system, the dissolution fluid path having an output end in fluid communication with the vial and an input end attached to a pressure vessel containing a dissolution medium. A delivery fluid path is also included in the system having a first end hermetically attached to the vial to transport therefrom a mixture of dissolved pharmaceutical product and dissolution medium and a second end connected to a receiving vessel to receive the mixture. A dissolution fluid path valve is positioned between the pressure vessel and the dissolution fluid path to control flow of the dissolution medium, and a delivery fluid path valve is also included in the fluid path system to control flow of the mixture from the delivery fluid path to the receiving vessel. Figure 1
Abstract:
A magnetizer (304) for magnetizing permanent magnets (308) positioned in-situ a mechanical member (302) is disclosed. The magnetizer comprises at least one primary superconducting coil (324) configured to project a magnetic field flux configuration of a first type to at least a portion of a distal volume of a first type, and at least two auxiliary coils (326, 328) symmetrically disposed about the at least one primary superconducting coil and configured to project magnetic field flux configurations of a second type to at least a portion of a distal volume of a second type. A method (700) of magnetizing a permanent magnet in-situ within a mechanical member is also disclosed.
Abstract:
A fluid path system includes a vial containing a pharmaceutical product therein. A dissolution fluid path is also included in the fluid path system, the dissolution fluid path having an output end in fluid communication with the vial and an input end attached to a pressure vessel containing a dissolution medium. A delivery fluid path is also included in the system having a first end hermetically attached to the vial to transport therefrom a mixture of dissolved pharmaceutical product and dissolution medium and a second end connected to a receiving vessel to receive the mixture. A dissolution fluid path valve is positioned between the pressure vessel and the dissolution fluid path to control flow of the dissolution medium, and a delivery fluid path valve is also included in the fluid path system to control flow of the mixture from the delivery fluid path to the receiving vessel.
Abstract:
A magnetizer (304) for magnetizing permanent magnets (308) positioned in-situ a mechanical member (302) is disclosed. The magnetizer comprises at least one primary superconducting coil configured to project a magnetic field flux configuration of a first type to at least a portion of a distal volume of a first type, and at least two auxiliary coils symmetrically disposed about the at least one primary superconducting coil and configured to project magnetic field flux configurations of a second type to at least a portion of a distal volume of a second type. A method (700) of magnetizing a permanent magnet in-situ within a mechanical member is also disclosed.
Abstract:
A fluid path system includes a vial containing a pharmaceutical product therein. A dissolution fluid path is also included in the fluid path system, the dissolution fluid path having an output end in fluid communication with the vial and an input end attached to a pressure vessel containing a dissolution medium. A delivery fluid path is also included in the system having a first end hermetically attached to the vial to transport therefrom a mixture of dissolved pharmaceutical product and dissolution medium and a second end connected to a receiving vessel to receive the mixture. A dissolution fluid path valve is positioned between the pressure vessel and the dissolution fluid path to control flow of the dissolution medium, and a delivery fluid path valve is also included in the fluid path system to control flow of the mixture from the delivery fluid path to the receiving vessel.
Abstract:
A penetration assembly 500 for a cryostat 101 is presented. The penetration assembly 500 includes a wall member 502 having a first end 504 and a second end 506 and configured to alter an effective thermal length of the wall member, where a first end 504 of the wall member 502 is communicatively coupled to a high temperature region and the second end 506 of the wall member is communicatively coupled to a cryogen 118 disposed within a cryogen vessel 104 of the cryostat 101.